Stool markers for colorectal cancer screening: Future considerations

Digestive Diseases

Volumn 14, Issue 3, 1996, Pages 132-144

  Ahlquist, David A ^a   Gilbert, Jorge A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Colorectal cancer screening; Stool testing

Indexed keywords

CALGRANULIN; MEMBRANE ANTIGEN; MUCIN; NERVE CELL ADHESION MOLECULE; TUMOR MARKER;

CHEMISTRY; COLORECTAL TUMOR; CYTOLOGY; FECES; HUMAN; OCCULT BLOOD; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTIGENS, SURFACE; COLORECTAL NEOPLASMS; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MUCINS; NEURAL CELL ADHESION MOLECULES; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0030133351     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171545     Document Type: Article

References (78)

1. Boland CR: Malignant lumors of the colon; in Yamada T (ed): Textbook of Gastroenterology. Philadelphia. Lippincott, 199l, pp 1768-1813.
2. Feldman AR, Kessler L, Myers MH, Naughton MD: The prevalence of cancer, estimates based on the Connecticut Tumor Registry. N Engl J Med 1986;315:1394-1397.
3. Holdeman LV, Good IJ, Moore WEC: Human fecal flora: Variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Micro 1976;31:359-375.
4. Stephen AM, Cummings JH: Mechanism of action of dietary fiber in the human colon. Nature 1980;284: 283-284.
5. Simon JB: Occult blood screening for colorectal carcinoma: A critical review. Gastroenterology 1985:88: 820-837.
6. Ahlquist DA: Occult gastrointestinal bleeding; in Yamada T (ed): Tcxl-bookofGastroentcrology. New York. Lippincott. 1991, pp 616-634.
7. Ahlquist DA, Wieand US, Moertel CG, McGill DB, Loprinzi CL, O’connell MJ, Mailliard JA, Gerstner JB, Pandya K, Ellefson RD: Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemo-Quant and Hemoccult. JAMA 1993: 269:1262-1267.
8. Bang KM, Tillett S, Hoar SK, Blair A, McDougall V: Sensitivity of fecal Hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening. J Occup Med 1986:28: 709-713.
9. Rozen P: Screening for colorectal neoplasia in the Tel Aviv area: Cumulative data 1979-89 and initial conclusions, lst J Med Sci 1992; 28(suppl): 8-20.
10. Jahn H, Joergensen OK, Kronborg O, Fenger C: Can Hemoccult II replace colonoscopy after radical surgery for colorectal cancer or after polypectomy? Dis Colon Rectum 1992;35:253-256.
11. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA: Fecal blood levels in health and disease: A study using HemoQuant. N Engl J Med 1985;312:1422-1428.
12. Crowley ML, Freeman LD, Mottet MD, Strong RM, Sweeney BF, Brower RA, et al: Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol 1983:5:127-130.
13. Ahlquist DA, McGill DB, Fleming JL, Schwartz S, Wieand HS, Rubin J, Moertel CG: Patterns of occult bleeding in asymptomatic celoreetal cancer. Cancer 1989:319:1826-1830.
14. Mandel JS, Bond JH, Church TR, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood N Engl J Med 1993:328: 1365-1371.
15. Selby JV, Friedman GD, Quesen-berry CP, et al: Effect of fecal occult blood testing on mortality from colorectal cancer: A case-control study. Ann Intern Med 1993; 118:1-6.
16. Winawer SJ, Zauber AG, Ho MN, et al: Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993:329:1977-1981.
17. Selby JV, Friedman GD, Quesen-bcrry CP, et al: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992:326:653-657.
18. Dale I, Brandtzaeg P, Fagerol MK, Scott H: Distribution of a new myciomonocvtic antigen (L-l) in human peripheral blood leukocytes. Am J Clin Pathol 1985:84:24-34.
19. Roseth AG, Fagerhol MK, Aadland E, et al: Assessment of the neutrophil dominating protein calprotectin in feces: A mcthodologic study. Scand J Gastroenterol 1992;27: 793-798.
20. Roseth AG, Kristinsson J, Aadland E, Schjonsby H, Nygaard K, Fagerhol MK: Calprotectin: A sensitive marker of gastrointestinal neoplasia. Gastroenterology 1993:104:A390.
21. Fagcrhol MK, Andersscn KB, Naess-Andrescn CF, Brandtzaeg P, Dale I: Calprotectin (the LI leukocyte protein): in Smith VK. Dedman JR (eds): Stimulus Response Coupling: The Role of Intracellular Calcium-Binding Proteins. Boca Raton. CRC Press. 1990, pp 187-210.
22. Gilbert JA, Ahlquist DA, Mahoney DW, Zinsmeister AR, Rugin J, Ellefson RD: Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin. Gastroenterology 1995;108:A474.
23. Dubrow R, Kim CS, Eldred AK: Fecal lysozyme: An unreliable marker for colorectal cancer. Am J Gastroenterol 1992;87:617-621.
24. Roseth AG, Kristinsson J, Nygaard K, et al: Faecal lactoferrin, a novel marker of colorectal cancer in rats: A longitudinal in vivo study. Gastroenterology 1995;108:A530.
25. Nakagama T, Yasuoko H, Kishino T, et al: ELISA for occult fecal albumin. Lancet 1992;i: 1368-1369.
26. Dubrow R, Yannieli L: Fecal protein markers of colorectal cancer. Am J Gastroenterol 1992:87:854-858.
27. Kim YS: Mucin glycoproteins in gastrointestinal malignancies and metastasis. Eur J Gastroenterol Hepatol 1993:5:219-225.
28. Ho SB, Niehans GA, Lyftoglu C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993:53:641-651.
29. Boland CR, Montgomery CK, Kim YS: Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation. Proc Natl Acad Sci USA 1982; 79:2051-2055.
30. Hoskins LC: Mucin degradation in the human gastrointestinal tract and its significance to enteric microbial ecology. Eur J Gastroenterol Hepatol 1992:54:205-213.
31. Tsai HH, Rhodes JM: Mucus glycoprotein alterations in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1993;5:214-218.
32. Itzkowilz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bidgee WL: Expression of Tn. Sialo-syl Tn and T antigens in human colon cancer. Cancer Res 1989:49: 197-204.
33. Ho S: The use of mucosal biopsy markers to predict colon cancer risk. Gastrointest Endose Clin N Am 1993:3:623-638.
34. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS: Sialosyl Tn: A novel mucin antigen associated with poor prognosis in colorectal cancer patients. Cancer 1990;66:1960-1966.
35. Yuan M, Chang XP: Detection of mucin core peptide MUC-2 and S-Tn antigen in feces of patients with colorectal cancer. Gastroenterology 1993; 104: A465.
36. Lotan R, Skutalsky E, Danon D, Sharon H: The purification, composition, and specificity of anti-T lectin from peanut (Arachis hypogaea). J Biol Client 1975:250:8518-8522.
37. Camp E, Condom E, Palacin A, Quesada E, Cardesa A: Lectin binding patterns in normal and neoplastic colonic mucosa. Dis Col Rectum 1988:31:11:892-899.
38. Elsayed AM, Shamsuddin AM: Detection of altered glycoconjugate in preneoplastic and neoplastic human large intestinal epithelium by galactose oxidase-Schiff sequence. Lab Invest 1987:56:224.
39. Shamsuddin AM, Elsayed AM: A test for the detection of colorectal cancer. Human Pathol 1988; 19:7-12.
40. Shamsuddin AM, Sakamoto K: Carbohydrate tumor marker: Basis for a simple test for colorectal cancer; in Jacobs MM (ed): Diet and Cancer: Markers, Prevention, and Treatment. Plenum Press. New York, 1994. Vol 8.pp 85-98.
41. Watanabe H, Mouri I, Yamaguchi Y, Yamakawa O, et al: The colon mucus test 111 comparison with fecal occult blood test in the detection of gastrointestinal disease. DigEndosc 1992;4:139-146.
42. Dian-yuan Z, Fu-cai F. Ya-li Z, Zuo-sen L, et al: Comparison of Sham’s test for rectal mucus to an immunological test for fecal occult blood in large intestinal carcinoma screening. Chin Med J 1993:106:739-742.
43. Zotter S, Lossnitzer A, Hageman PC, et al: Immunohistochemical localization of (he epithelial marker MAM-6 in invasive malignancies and highly dvsplastic adenomas of the large intestine. Lab Invest 1987; 57:193-199.
44. Gilbert JA, Ahlquist DA, Mahoney D, Burgart LJ, Zinsmeister AR, Harrington JJ, Roche PC: Candidate stool markers for colorectal cancer screening: An immunohistochemical analysis. Gastroenterology 1995; 108:A473.
45. Quirke P, Dixon MF, Clayden AD, et al: Prognostic significance of DNA ancuploidy and cell proliferation in rectal adenocarcinoma. J Pathol 1987:151:285-291.
46. Shorter RG, Moertcl CG, Titus JL, Reitemeier RJ: Cell kinetics in the jejunum and rectum of man. Am J Dig Dis 1964;9:760-763.
47. Iyengar V, Albaugh GP, Lohani A, Nair PP: Human stools as a source of viable colonic epithelial cells. FASEB 1991;5:2856-2859.
48. Albaugh GP, Iyengar V, Lohani A, et al: Isolation of exfoliated colonic epithelial cells, a novel non-invasive approach to the study of cellular markers. Int J Cancer 1992:52:347-350.
49. Iwanaga T, Han H, Adachi K, Fujita T: A novel mechanism for disposing of effete epithelial cells in the small intestine. Gastroenterology 1993; 105:1089-1097.
50. Bedi A, Pasricha PJ, Akhtar T, et al: Inhibition of apoptosis during the development of colorectal cancer. Cancer Res 1995;55:1811-1816.
51. Roscnbach O: Über die Anwesenheit von Geschwulstpartikeln in dem durch die Magenpumpe entleerten Mageninhalte bei Karzino-ma ventriculi. Dtsch Med Wo-chcnschr 1882;33:452.
52. Reincboth T: Die Diagnose des Magenkarzinoms aus Spülwasser und Erbrochenem. Dtsch Arch Klin Med I896;58:63.
53. Cameron AB, Thabet RJ: Recovery of malignant cells from enema returns in carcinoma of the colon. Surg Forum 1959;10:30-33.
54. Raskin HF, Palmer WL, Kirsner JB: Exfoliative cytology in diagnosis of cancer of the colon. Dis Colon Rectum 1959;2:46-69.
55. Bader GM, Papanicolaou GN: The application of cytology in the diagnosis of cancer of the rectum, sigmoid. and descending colon. Cancer 1952;5:307-310.
56. Gordon II, Rypins EB, Wuerker RB, Janowatz JJ: Cytologic detection of colorectal cancer after administration of oral lavage solution. Cancer 1991:68:106-110.
57. Rosman AS, Feinntan L, Fedcrman Q, et al: Diagnosis of colon cancer by lavage cytology using an orally administered balanced electrolyte solution (Colytc): Gastroenterology 1988;94:A386.
58. Tobi M, Darmon E, Phillips T, et al: Increased expression of a putative adenoma-associated antigen in pre-colonoscopic effluent of patients with colorectal cancer. Cancer Lett 1990:51:21-25.
59. Rozen P, Tobi M, Darmon E, Kaufman L: Colonic exfoliative cytology: A simplified method of collection and initial results. Acta Cytol 1990: 35:627-631.
60. Darmon E, Tobi M, Rozen P: Newer tests on the colonic effluent for identifying persons with colorectal-neoplasia; in Rozen P, Reich CB. Winawer SJ (eds): Large Bowel Cancer: Policy. Prevention. Research, and T reatment. Basel, Karger, 1991, pp 236-247.
61. Rosenberg IL, Giles GR: The value of colonic exfoliative cytology in the diagnosis of carcinoma of the large intestine. Dis Col Rect 1977:10:1-10.
62. Feraron ER, Vogelstcin B: A genetic model for colorectal tumorigencsis. Cell 1990;61:759-767.
63. Mulcahy HE, O’donoghue DP: Molecular biology: Setting the stage in colorectal cancer? Gut 1993:34: 1476-1477.
64. Scott N, Quirke P: Molecular biology of colorectal neoplasia. Gut 1993; 34:289-292.
65. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P. Vogelstein B: Identification of ras oncogen mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-105.
66. Tobi M, Luo FC, Roani Z: Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal cancer. J Natl Cancer Inst 1994:86:1007-1010.
67. Yamashita N, Minamoto T, Ochiai A, et al: Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108:434-440.
68. Cunningham J, Lust JA, Schaid DJ, et al: Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-1980.
69. Ma S, Wong RKH, Kikendall JW, Nair PP: Detection of p53 gene mutations in exfoliated human colonic epithelial cells isolated from stools of subjects undergoing colonoscopy. Gastroenterology 1993; 104:A423.
70. Ho S, Toribara N, Bresalier RS, Kim YS: Biochemical and other markers of colon cancer. Gastroenterol Clin N Am 1988;17:811-830.
71. Brinkley BR, Chafoulecs JG: Cyto-skeleton and the transformed phenotype of malignant cells; in Wol-man SR. Mastromarino AJ (eds): Markers of Colonic Cell Differentiation. Progress in Cancer Research and Therapy. Raven Press. New York. 1984, vol 29, pp 1-67.
72. Dudonet B, Jacob L, Benzeboc P, et al: Presence of villin a tissue-specific cytoskeletal protein, in sera of patients and an initial clinical evaluation of its value for the diagnosis and follow-up of colorectal cancers. Cancer Res 1990;50:438-442.
73. Moertcl CG, Fleming TR, MacDonald JS, et al: An evaluation of the carcinoembryonic antigen (CEA) text for monitoring patients with resected colon cancer. JAMA 1993; 270:943-947.
74. Stubbs RS, Nadkami DM, Monsey HA: Fecal carcinoembryonic antigen (CEA) in patients with large bowel cancer. Eur J Surg Oncol 1987:13:433.
75. Fujimoto S, Kitsukawa Y, Itoh K: Clinical value of fecal CEA as an aid to diagnosis. Cell Mol Biol 1979:25: 153-161.
76. Shimano T, Okuda H, Monden T, Inaji H, Mori T: Usefulness of carci-nocmbryonic antigen measurement in feces of patients with colorectal cancer. Dis Colon Rectum 1987;30: 607-610.
77. Sugano K, Ohkura H, Hirohashi S, Shimosato Y, Sakurai Y, Kodaira S, Abe O: Detection of increased fecal carcinoembryonic antigen and its characterization as a membrane-bound form in colorectal carcinoma and other gastrointestinal disorders. Jpn J Cancer Res 1989;80:1156-1160.
78. Lloyd KO: Immunology; in Cohen AM, Winawcr SJ. Friedman MA, Gunderson LG (eds): Cancer of the Colon. Rectum and Anus. New York. McGraw-Hill, 1995, pp 165-174.